Jason Foster, MBA, Ori Biotech, London, UK, discusses barriers facing patients access to cell and gene therapies as well as solutions to address these challenges. Collection of patient cells increases the complexity of the supply chain, with increased travel and cryopreservation costs needed for the product. Large-scale manufacturing advanced therapies is additionally challenging due to the inconsistent nature of the starting material, as well as the need for personnel with a specialized skillset. Multiple strategies such as automation and decentralized approaches may provide a solution to these issues. This interview took place at Advanced Therapies Week 2022.